ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0611

Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study

Fadi Kharouf1, Pankti Mehta2, Qixuan Li2, Dafna D. Gladman3, Laura Whitall Garcia4 and Zahi Touma5, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2025

Keywords: Cohort Study, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Venous thromboembolism (VTE) is a known complication of systemic lupus erythematosus (SLE), yet there is a lack of high-quality studies specifically focused on lupus nephritis (LN). This study aimed to assess the frequency of VTE in patients with LN and identify risk factors for its development.

Methods: We included patients with biopsy-proven LN from a prospective observational cohort followed between 1970 and 2024. The primary outcome, VTE occurring after the onset of LN, was monitored longitudinally, and the time to the first event was calculated. Time-dependent univariable and multivariable cause-specific Cox proportional hazards models were used to identify factors associated with the first VTE, with death considered a competing risk.

Results: A total of 324 patients were included in the study, with a mean age of 34.2 years [IQR, 25.9, 43.0] at baseline (Table 1). The cohort was predominantly female (279 patients, 86.1%) and the majority of patients identified as White (184 patients, 57%). Over a long-term follow-up period of 9.9 years [IQR: 5.0–16.4], 30 patients (9.3%) developed at least one VTE, with a median time to the first event from LN onset of 4.3 years [IQR, 0.1, 14.1] (Figure 1). Most events were isolated (86.7%), including 19 deep vein thromboses (DVTs, 59.4%), 5 pulmonary embolisms (PEs), and 2 events involving other venous beds. In the multivariable model, the following factors were independently associated with the development of VTE: the SLEDAI-2K score (HR = 1.05, 95% CI: 1.01–1.10) and proteinuria level (HR = 1.26, 95% CI: 1.08–1.47) (Table 2).

Conclusion: VTE can complicate the course of LN at any stage, mostly manifesting as DVT and PE. Disease activity and proteinuria are the primary risk factors for its development.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: F. Kharouf: None; P. Mehta: None; Q. Li: None; D. Gladman: AbbVie, 2, 5, Amgen, 2, 5, AstraZeneca, 2, BMS, 2, 5, Eli Lilly, 2, 5, Janssen, 5, Johnson & Johnson, 2, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, UCB, 2, 5; L. Whitall Garcia: None; Z. Touma: AbbVie, 2, AstraZeneca, 1, 2, 5, GSK, 2, 5, Merck KgaA, 2, Novartis, 1, Roche, 2, Sarkana Pharma Inc, 2, UCB/Biopharma, 1, 2.

To cite this abstract in AMA style:

Kharouf F, Mehta P, Li Q, Gladman D, Whitall Garcia L, Touma Z. Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/venous-thromboembolism-in-patients-with-lupus-nephritis-frequency-and-risk-factors-a-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/venous-thromboembolism-in-patients-with-lupus-nephritis-frequency-and-risk-factors-a-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology